Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of JK07 in HFpEF
NCT05322616Phase 1Withdrawn
- Sponsor
- Salubris Biotherapeutics
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Peptides, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing JK07 with Placebo (2 arms). Primary endpoint: Safety Assessment at Day 28. Planned start Oct 2022; status: withdrawn.
02
Drugs
JK07
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05322616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322616.